Effectiveness of icatibant for treatment of hereditary angioedema attacks is not affected by body weight: findings from the Icatibant Outcome Survey, a cohort observational study
Abstract Background Icatibant is a bradykinin B2-receptor antagonist used for the treatment of hereditary angioedema attacks resulting from C1-inhibitor deficiency. Treatment is not adjusted by body weight however the impact of body mass index (BMI) on the effectiveness of icatibant is not documente...
Main Authors: | Teresa Caballero, Andrea Zanichelli, Werner Aberer, Marcus Maurer, Hilary J. Longhurst, Laurence Bouillet, Irmgard Andresen, the IOS Study Group |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2018-03-01
|
Series: | Clinical and Translational Allergy |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s13601-018-0195-x |
Similar Items
-
Breakthrough attacks in patients with hereditary angioedema receiving long-term prophylaxis are responsive to icatibant: findings from the Icatibant Outcome Survey
by: Werner Aberer, et al.
Published: (2017-07-01) -
Management of hereditary angioedema in Japan: Focus on icatibant for the treatment of acute attacks
by: Michihiro Hide, et al.
Published: (2021-01-01) -
Elderly versus younger patients with hereditary angioedema type I/II: patient characteristics and safety analysis from the Icatibant Outcome Survey
by: Anette Bygum, et al.
Published: (2019-07-01) -
Real-world outcomes in hereditary angioedema: first experience from the Icatibant Outcome Survey in the United Kingdom
by: Hilary J. Longhurst, et al.
Published: (2018-08-01) -
Improvement in diagnostic delays over time in patients with hereditary angioedema: findings from the Icatibant Outcome Survey
by: Andrea Zanichelli, et al.
Published: (2018-10-01)